Your browser doesn't support javascript.
loading
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.
Assié, Jean-Baptiste; Crépin, Florian; Grolleau, Emmanuel; Canellas, Anthony; Geier, Margaux; Grébert-Manuardi, Aude; Akkache, Nabila; Renault, Aldo; Hauss, Pierre-Alexandre; Sabatini, Marielle; Bonnefoy, Valentine; Cortot, Alexis; Wislez, Marie; Gauvain, Clément; Chouaïd, Christos; Scherpereel, Arnaud; Monnet, Isabelle.
  • Assié JB; GRC OncoThoParisEst, Service de Pneumologie, Centre Hospitalier IntercommunaI, UPEC, 94000 Créteil, France.
  • Crépin F; Functional Genomics of Solid Tumors Laboratory, Centre de Recherche des Cordeliers-INSERM-Sorbonne Université-Université Paris Cité, 75006 Paris, France.
  • Grolleau E; Department of Pulmonary and Thoracic Oncology, University of Lille, University Hospital Center (CHU) of Lille, 59000 Lille, France.
  • Canellas A; Service de Pneumologie Aiguë Spécialisée et Cancérologie Thoracique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.
  • Geier M; Department of Pneumology and Thoracic Oncology, Tenon Hospital, APHP, GRC Theranoscan and Curamus Sorbonne Université, 75020 Paris, France.
  • Grébert-Manuardi A; Institut de Cancerologie, Centre Hospitalier Régional Universitaire de Brest, Hôpital Morvan, 29200 Brest, France.
  • Akkache N; Service de Pneumologie, Centre Hospitalier Contentin, 50100 Cherbourg, France.
  • Renault A; Service de Pneumologie, Centre Hospitalier Aix, 13100 Aix-en-Provence, France.
  • Hauss PA; Service de Pneumologie, Centre Hospitalier Pau, 64000 Pau, France.
  • Sabatini M; Service de Pneumologie, Centre Hospitalier IntercommunaI, 76503 Louviers, France.
  • Bonnefoy V; Service de Pneumologie, Centre Hospitalier Général, Côte-Basque, 64100 Bayonne, France.
  • Cortot A; GRC OncoThoParisEst, Service de Pneumologie, Centre Hospitalier IntercommunaI, UPEC, 94000 Créteil, France.
  • Wislez M; Department of Pulmonary and Thoracic Oncology, University of Lille, University Hospital Center (CHU) of Lille, 59000 Lille, France.
  • Gauvain C; Team Inflammation Complement and Cancer, Centre de Recherche des Cordeliers-INSERM-Sorbonne Université-Université Paris Cité, 75006 Paris, France.
  • Chouaïd C; Thoracic Oncology Unit, Pulmonology Department, APHP, Hôpital Cochin, 75014 Paris, France.
  • Scherpereel A; Department of Pulmonary and Thoracic Oncology, University of Lille, University Hospital Center (CHU) of Lille, 59000 Lille, France.
  • Monnet I; GRC OncoThoParisEst, Service de Pneumologie, Centre Hospitalier IntercommunaI, UPEC, 94000 Créteil, France.
Cancers (Basel) ; 14(6)2022 Mar 15.
Article en En | MEDLINE | ID: mdl-35326648
ABSTRACT
Backgrounds Malignant pleural mesothelioma (MPM) is a cancer with poor prognosis. Second-line and onward therapy has many options, including immune-checkpoint inhibitors with demonstrated efficacy 10−25% objective response rate (ORR) and 40−70% disease-control rate (DCR) in clinical trials on selected patients. This study evaluated real-life 2L+ nivolumab efficacy in MPM patients and looked for factors predictive of response.

Methods:

This retrospective study included (September 2017−July 2021) all MPM patients managed in 11 French centers.

Results:

The 109 enrolled patients' characteristics were median age 69 years; 67.9% men; 82.6% epithelioid subtype. Strictly, second-line nivolumab was given to 51.4%. Median PFS and OS were 3.8 (3.2−5.9) and 12.8 (9.2−16.4) months. ORR was 17/109 (15.6%); 34/109 patients had a stabilized disease (DCR 46.8%). Univariable analysis identified several parameters as significantly (p < 0.05) prognostic of OS [HR (95% CI)] biphasic subtype 3.3 (1.52−7.0), intermediate Lung Immune Prognostic Index score 0.46 (0.22−0.99), progression on the line preceding nivolumab 2.1 (1.11−3.9) and age > 70 years 2.5 (1.5−4.0). Multivariable analyses retained only biphasic subtype 3.57 (1.08−11.8) and albumin < 25 g/L 10.28 (1.5−70.7) as significant and independent predictors.

Conclusions:

Second-line and onward nivolumab is effective against MPM in real life but with less effectiveness in >70 years. Ancillary studies are needed to identify the predictive factors.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Año: 2022 Tipo del documento: Article